Title	Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment
Author(s)	Kondo, Toru
Citation	Seminars in Cancer Biology, 82, 176-183 https://doi.org/10.1016/j.semcancer.2020.12.003
Issue Date	2022-07-01
Doc URL	https://hdl.handle.net/2115/90107
Rights	© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	journal article
File Information	YSCBI-D-20-00130_R1.pdf

Title: Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin,

genetic/epigenetic mutation and microenvironment

Toru Kondo

**Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido
University, Sapporo, 060-0815, Japan**

Correspondence: Toru Kondo
Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University
Kita-15, Nishi-7, Kita-ku, Sapporo 060-0815, Japan

Tel: +81-11-706-6082, Fax: +81-11-706-7870
E-mail: tkondo@igm.hokudai.ac.jp

Abstract

Glioblastoma (GBM) and other malignant tumours consist of heterogeneous cancer cells, including GBM-initiating cells (GICs). This heterogeneity is likely to arise from the following: different sets of genetic mutations and epigenetic modifications, which GICs gain in the transformation process; differences in cells of origin, such as stem cells, precursor cells or differentiated cells; and the cancer microenvironment, in which GICs communicate with neural cells, endothelial cells and immune cells. Furthermore, considering that various types of GICs can be generated at different time points of the transformation process, GBM very likely consists of heterogeneous GICs and their progeny. Because cancer cell heterogeneity is responsible for therapy resistance, it is crucial to develop methods of reducing such heterogeneity. Here, I summarize how GIC heterogeneity is generated in the transformation process and present how cell heterogeneity in cancer can be addressed based on recent findings.

Keywords: Glioblastoma (GBM) , GBM-initiating cells (GICs), heterogeneity, Temozolomide (TMZ), dihydroorotate dehydrogenase (DHODH)

1. Introduction

Glioblastoma (GBM) is a malignant glioma with a median survival of approximately 15 months [1,2]. Despite the development of multimodal treatments involving surgery, chemotherapy and radiotherapy, the overall survival rate of patients with GBM has not improved over the past few decades. The discovery of GBM-initiating cells (GICs) has strongly impacted the direction of GBM research, as these cells have been shown to possess strong tumourigenic ability and to be resistant to irradiation and anticancer drugs such as temozolomide (TMZ) [3-7]. It is therefore crucial to characterize GICs and to identify new methods and compounds that specifically eliminate GICs. Although researchers have elucidated essential factors and mechanisms associated with the characteristics and maintenance of GICs, the development of new therapeutic methods and the identification of anti-GIC compounds through screening remain problematic for the following reasons. First, it is uncertain whether all kinds of GICs from patients can be maintained using current culture methods. Second, there is little information about the heterogeneity of cultured GICs. Third, there is no method for maintaining GICs as a homogenous population in culture. In this review, I discuss these hurdles and present recent findings as possible approaches to overcome such challenges and treat GBM.

2. Tumour heterogeneity

2.1. Cell of origin in GBM

Cancers arise from cells that acquire genetic mutations, epigenetic regulation or both. To characterize cancer appropriately, it is also essential to determine the cell of origin as well as genetic/epigenetic alterations acquired. Globus and Kuhlenbeck have suggested that malignant brain tumours arise from cells residing in the ventricular/subventricular zone (VZ/SVZ), where neural stem cells (NSCs) exist [8]. Hopewell and Wright demonstrated that in the brains of mice, tumours were frequently induced from the VZ/SVZ when tumour promoters, such as 3,4-benzpyrene and 20-methylcholanthrene, were transplanted into various regions [9]. Furthermore, Holland et al. succeeded in inducing GBM-like tumours in transgenic mice that express the avian leukaemia virus receptor; expression was controlled by the promoter of either the NSC marker Nestin or the astrocyte marker Glial fibrillary acidic protein via virus infection with the *Ras* oncogene [10]. In addition, DePinho and colleagues induced malignant glioma in mice by transplanting NSCs that express the constitutively active form of *epidermal growth factor receptor* (*EGFR*) [11]. Kondo and colleagues showed that the combination of oncogenic *Ras* overexpression and p53 inhibition induced NSCs and oligodendrocyte precursor cells (OPCs) to transform into GICs, which formed brain tumours with pathological features of human GBM and that the same mutations did not transform the differentiated mature oligodendrocytes but did astrocytes to form non-transplantable lower grade tumours, suggesting that these cells need additional mutation(s) to transform into GICs [12-14]. These authors also revealed that OPCs lost their original characteristics and acquired NSC characteristics (reversion) during the transformation process [15,16]. Using *p53* and *type 1 neurofibroma* (*NF1*) mutant–mosaic analysis

with a double-marker (MADM) mouse model, Liu et al. found significant aberrant growth prior to malignancy only in OPCs but not in any other NSC-derived lineages or NSCs themselves [17]. Overall, these findings suggest that NSCs, OPCs and astrocytes are possible cells of origin for GBM and that non-NSCs acquire NSC characteristics in their transformation process, contributing to tumour heterogeneity, including GICs and differentiation marker-positive cancer cells (Fig. 1A).

2.2. Genetic/epigenetic mutations in GIC development

Among genes involved in GBM development, both the Cancer Genome Atlas Research Network and Parsons et al. have independently revealed that genes mutated in GBM are involved in three signalling pathways: p53 (approximately 90%), retinoblastoma (Rb) (approximately 80%) and receptor tyrosine kinase (RTK) (approximately 90%) pathways [18,19].

Loss of p53 function is essential to promote accelerated cell proliferation and malignant transformation [20]. Indeed, over 65% of human gliomas have been shown to contain *TP53* gene deletions and mutations [21]. Moreover, additional evidence indicates that other p53 signalling factors, including *Murin-double-minute 2* (*MDM2*), which binds to, destabilizes, and inactivates p53, and *chromodomain helicase DNA binding domain 5* (*Chd5*), which regulates cell proliferation, cellular senescence, apoptosis, and tumourigenesis, are mutated in malignant glioma [22,23]. Although the effector molecule of the p53 pathway is the p21 cyclin-dependent kinase (cdk) inhibitor, which regulates the progression of cells through the G1 cell cycle phase, it has not been demonstrated that the *p21* gene itself is an oncogenic target in human cancers.

Mutations in the Rb signalling pathway, including *cdk4* amplification and *p16/Ink4a* deletion, are frequently identified in many types of malignant tumours [24]. The hypophosphorylated form of Rb sequesters the E2F transcription factor and arrests cells at the G1 checkpoint. After Rb is hyperphosphorylated by cyclin D and the cdk4/6 complex, phosphorylated Rb releases E2F, which induces expression of cell cycle regulators, and the cells enter S phase. In contrast, the p16/Ink4a cdk inhibitor binds to cdk4/6, prevents complex formation by cdk4/6 and cyclin D, and maintains Rb hypophosphorylation [25].

Signalling pathways (Ras/Raf/MAPK and phosphatase tensin homologue (PTEN)/AKT pathways) of RTKs, including *EGFR*, *platelet-derived growth factor (PDGF) receptor α* and *transforming growth factor-beta (TGFβ) receptor*, many of which participate in the maintenance of GICs and amplifying precursors, are also frequently mutated in tumours [26]. For example, *EGFR* is overexpressed in up to 60% of gliomas [21]. It has also been shown that the small GTP protein *Ras*, an essential oncogene, and its negative regulator *NF1* are mutated in many types of human cancers, including glioma; moreover, *PTEN*, which inhibits the function of Akt-activating phosphoinositol tri-phosphate kinase (PI3K), is frequently inactivated in malignant glioma [27]. In addition, TGFβ has been shown to induce the proliferation of GICs through stimulation of the PDGFβ and LIF signalling pathways [28,29]. Furthermore, TGFβ activates the Sox4-Sox2 axis and polycomb complex protein Bmi1 (B lymphoma Mo-MLV insertion region 1 homologue), both of which are essential regulators in GIC, to maintain tumourigenesis [30,31]. Considering that TGFβ is an inducer of regulatory T cells, which inhibit immune system activation, these results suggest that TGFβ is a central player in gliomagenesis. On the basis of these findings, many researchers have

revealed that various combinations of oncogene activation and tumour suppressor gene inhibition cause NSCs, OPCs or astrocytes to become GICs, apparently contributing to heterogeneity in progressive cancer.

Similar to genetic mutations, epigenetic modifications have been shown to be involved in GBM development. Abdouh et al. found that both polycomb repressive complex1 (PRC1) and 2 (PRC2) are involved in the self-renewal of GICs and their tumourigenesis: both oncogenes Bmi1 and EZH2, the main components of PRC1 and PRC2, respectively, are expressed in CD133-positive GICs and GBM. *Bmi1* knockdown prevents GIC proliferation and tumourigenesis by inducing apoptosis and differentiation, while inhibition of EZH2 impairs GBM growth [32].

In another study, Gallo et al. showed that expression of the histone 3 variant H3.3 is negatively regulated by the epigenetic repressor mixed lineage leukaemia 5 (MLL5), which controls self-renewal and tumourigenesis by orchestrating reorganization of the chromatin structure. Given that H3.3 prevents self-renewal of GBM cells and promotes their differentiation, the authors concluded that MLL5/H3.3-associated epigenetic status maintains self-renewal hierarchies in GBM [33].

Gene expression profiles of GICs as well as bulk tumours have revealed that GICs were classified into four molecular subtypes, classical, pro-neural (PN), mesenchymal (MES) and neural [34]. MES-GICs display more aggressive phenotypes than the others and are resistant to chemoradiotherapies, resulting worse prognosis. It has also been shown that GICs are derived from PN-GICs and MES-GIC but not from classical-type GBM. Wang et al. addressed whether PN-GICs and/or MES-GICs are sufficient to generate GBM heterogeneity [35]. Using single-cell/nucleus RNA sequencing of 28 gliomas and single-cell assays for transposase-accessible chromatin

sequencing, these authors elegantly showed that GICs reside on a single axis of variation ranging from PN to MES. *In silico* lineage tracing using transcriptome and genetics analyses has also revealed that MES-GICs are progenitor cells of PN-GICs. Correctively, these results elucidate the lineage relationship between glioma cell types further generate GBM heterogeneity.

It is likely that cell of origin, genetic/epigenetic mutations, GIC microenvironment or these combination generate the molecular subtypes in GBM. According to Bhat et al., expression of *transcriptional coactivator with PDZ-binding motif* (*TAZ*, also known as *WW domain-containing transcription regulator 1*, *WWTR1*) is lower in PN-GBMs and lower-grade gliomas than in MES-GBMs due to hypermethylation of the *TAZ* promoter [36]. The researchers demonstrated that knockdown of *TAZ* in MES GICs prevents proliferation, invasion and tumourigenesis but that its overexpression in PN GICs and NSCs induces expression of MES markers and their transdifferentiation into osteoblasts and chondrocytes. These findings indicate that *TAZ* promoter methylation status determines MES phenotypes in GBMs. Taken together, combined genetic/epigenetic mutations cause cell of origin to transform GICs.

Recent progress of genome editing technology make it possible to manipulate specific genetic/epigenetic changes in GICs [37]. We can normalize genetic mutations or delete oncogenes using a combination of CRISPR-associated 9 nuclease (Cas9) and specific signal guide RNA (sgRNA). In addition, the finding of a catalytically inactive Cas9 (dCas9) enabled to manipulate gene expression, positively and negatively. Using dCas9 fused with VP64 transcriptional activation domain (dCas9-VP64) and a specific single guide RNA (sgRNA), Maeder et al. have successfully shown to activate expression of VEGFA and NTF3 in human cells [38]. Gao et al. have also succeeded to

induce mouse embryonic fibroblast to become induced pluripotent stem cells using dCas9-VP64 and sgRNA targeting Oct4 and Nanog [39]. Gilbert et al. demonstrated that combination of dCas9 fused with Krüppel-associated box (KRAB) domain of Kox1 (dCas9-KRAB) and sgRNA repressed expression of endogenous target genes, trasnferrin receptor and chemokine receptor type 4, in HeLa cells [40]. Taken together, these findings suggested that we can modify expression of target genes positively and negatively in GICs, once we establish its delivery system into GICs.

2.3. Oncogene or tumour suppressor gene, the first hit in GIC development

In the beginning of tumorigenesis, the cell of origin of cancer undergoes either genetic mutation or epigenetic alteration (first hit). The mutated cells (pre-transformed cells) proliferate and then acquire further different mutations (second hit, third hit, further hits) and eventually transform into cancer cells (Fig. 1B). After the first hit in tissue-specific stem cells, they generate pre-transformed stem cells and differentiating (precursor) cells via asymmetric division. Pre-transformed stem/precursor cells are thought to readily become GICs through second or third hit acquisition, whereas non-proliferating/differentiated pre-transformed cells may not transform into GICs as these cells do not easily acquire genetic mutations, suggesting that the first hit may occur in tumour suppressor genes and increase the tumorigenicity by accelerating proliferation.

On the other hand, there are many evidences that oncogenes are the first targets in tumorigenesis, even though oncogene activation induces cellular senescence, a state of permanent cell-cycle arrest [41]. For instance, the premalignant tumours, including Nevi and colon adenomas, have been shown to increase the expression of senescence associated beta-gal and INK4A, definitive markers of cellular senescence [42,43].

Nonetheless, when premalignant cells lose senescence mediators, such as p53 and the histone methyltransferase of lysine 9 in histone 3 that is involved in the heterochromatin formation, the cells bypass senescence states and transform into malignant tumours, raising a question of how premalignant tumour cells lose the expression of senescence mediators in their progression. Feng et al have recently uncovered that proto-oncoprotein c-Myc, one of downstream effectors of EGFR, not only drives cell proliferation but also inactivates p53 by inducing the Long noncoding RNA Inactivating p53 (MILIP) [44]. Ye et al have shown that Zeranol, produced from a natural carcinogenic product Zearalenone, induced heterochromatin formation in p53 promoter by the DNA methyltransferase 1-dependent manner, preventing the p53 expression [45]. Ladds et al have also found that inhibitors of dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis pathway, killed melanoma cells by increasing p53 synthesis [46]. These findings suggest that various types of pre-transformed cells obtain different mutations/modifications at different time points in their transformation process, generating heterogeneity in cancer, although it remains to elucidate how and when genetic/epigenetic mutations happen.

2.4. GIC microenvironment

GICs as well as other CICs are likely retained in a special microenvironment, the GIC niche, formed by various types of cells, including endothelial cells (ECs), mesenchymal stem cells (MSCs), glial cells, neurons and immune cells (Fig. 1C). These niche cells express many factors, such as Notch ligands, TGFβ, interleukin-6 (IL-6), neuroligin-3 (NLGN3) and scavenger receptors, to maintain the stemness, proliferation and motility of GICs [47]. For example, Li and Neaves showed that ECs express the Notch ligands

Dll4 and *Jagged 1*, which activate Notch1 and 2 on GICs, and that GICs secrete VEGF, which promotes the migration and proliferation of both ECs and MSCs [48].

Zhou et al. demonstrated that periostin generated by GICs polarizes macrophages/microglia into the M2 phenotype (tumour-associated macrophages/microglia, TAMs) and induces GIC proliferation through integrin αvβ3 [49]. In fact, there is much evidence that TGFβ from TAMs induces expression of matrix metalloproteases (MMPs) in GICs and promotes their invasion and that TGFβ from GICs also polarizes macrophages/microglia towards the TAM phenotype [50-53].

Two teams have shown that oesophageal cancer-related gene 4 (Ecrg4, also known as Chromosome 2 open reading frame 40 (c2orf40) and Augurin), a hormone-like peptide, acts as a novel type of tumour suppressor [54-57]. Using mouse GIC models, Moriguchi et al. found that *Ecrg4*-deficient GICs form tumours with characteristics resembling those of human GBM, including necrosis, haemorrhage and massive angiogenesis, in the brains of immunocompetent mice; in contrast, Ecrg4-expressing GICs tended to be eliminated by the immune system [58]. By using retrovirus-mediated expression cloning, the authors also identified scavenger receptors, including lectin-like oxidized LDL receptor-1, CD36 and Scarf1, as receptors of the Ecrg4 (71-132 amino acid) fragment. Furthermore, they reported that Ecrg4 (71-132) induces microglial secretion of inflammatory factors, such as IL-6 and tumour necrosis factor α, via the NF-κB signalling pathway [59]. Independently, Lee et al. discovered that the carboxy terminal fragment of Ecrg4 (133-148) is able to recruit microglia/macrophages and activated them, resulting in tumour regression [60]. The team also found that Ecrg4 (133-148) binds to Toll-like receptor 4, becomes internalized and modulates inflammation via non-canonical NF-κB signalling [61,62].

Collectively, these finding indicate that Ecrg4 is an essential intercellular communication factor in the GIC niche.

In addition, much evidence indicates that cross-talk between reactive astrocytes and GICs promotes tumour progression. Physical contact between astrocytes and glioma cells through gap junctions reduces the cytotoxicity of chemotherapeutic drugs in glioma cells [63]. IL-6 produced by astrocytes induces expression of cytomembrane *MMP14* in glioma cells and increases their migration and invasion via activation of MMP2 [64]. Astrocytes also supply L-glutamine, which is essential for GBM growth [65]. Furthermore, when GICs are transplanted into the brain parenchyma, they tend to migrate into the VZ/SVZ, move along the zone, and form disseminated tumours, suggesting that the VZ/SVZ cells secrete chemoattractants, such as Cxcl12 (also known as the stromal cell-derived factor, SDF1), for GICs and foster them as well as NSCs [66,67, Kondo et al., unpublished observation]. Thus, GICs are exposed to many factors in the niche, raising the question of whether all GICs can be maintained and expanded in GIC culture medium composed of serum-free NSC medium supplemented with basic FGF and EGF.

Neurons have been also shown to communicate with glioma cells by paracrine signaling and synapse formation. Venkatesh et al have shown that a soluble form of synaptic protein NLGN3, which is secreted from active neurons, increases glioma proliferation by inducing the expression of FOS and NLGN3 [68,69]. Yu et al revealed that glioblastoma cells keep proliferate by increasing the glypican 3-dependent synapse formation with tumour-surrounding neurons, while two groups demonstrated that neurons promote glioma progression through AMPA receptor-dependent neuron-glioma synaptic communication [70]. Although it is important to examine whether GICs also

communicate with neurons using same mechanism, these findings suggest that neuronal activity apparently contributes to gliomagenesis.

There is increasing evidence that extracellular microvesicles (EVs), such as exosomes, contain a portion of the mRNA, microRNA and proteins of the cells secreting them and are delivered to target cells that are nearby or even at a long distance and affect their characteristics [71-74]. Therefore, EVs have been extensively investigated as important intercellular communication factors. Skog et al. discovered that exosomes from GBM contain 6 angiogenic proteins, IL-6, IL-8, tissue inhibitor of metalloprotease (TIMP)1, TIMP2 and angiogenin, and activate angiogenesis. The authors also detected *EGFR variant III* (*EGFRvIII*) mRNA in the exosomes. Given that exosomes can be purified from body fluids, such as the blood and cerebrospinal fluid, exosomes may be employed to analyse the EGFRvIII status of GBM patients [75]. In addition, Gabrusiewicz et al. have shown that GIC-derived exosomes promote the immune-suppressive M2 phenotype in monocytes, which involves expression of programmed death-ligand 1, by transferring components of the STAT3 signalling pathway [76]. Mirzaei et al. have also reported that GIC-secreted exosomes contain tenascin-C, which suppresses T cell activity through interaction with $\alpha5\beta1$ and $\alpha v\beta6$ integrins on T cells [77]. However, Figueroa et al. found that glioma-associated MSCs release exosomes that induce proliferation of GICs and increase their clonogenicity by *miR-1587*-dependent downregulation of the nuclear receptor corepressor 1 [78].

GICs may be present both in the vascular niche, which continuously supplies nutrients and oxygen to GICs, and in the hypoxic area, where both nutrients and oxygen are relatively low. Therefore, it is likely that the gene expression profile of GICs is largely dependent on the niche. Indeed, according to Kathagen et al., there is a

reciprocal metabolic switch between the pentose phosphate pathway (PPP) and glycolysis in GICs [79], whereby expression of glycolytic enzymes is upregulated in hypoxia but downregulated in normoxia. In contrast, PPP enzymes display the inverse expression pattern. Exosomes from GBM cells in hypoxia were shown to contain hypoxia-regulated mRNAs and proteins and induce angiogenesis by activating ECs [80]. Moreover, Bao et al. revealed that GICs express hypoxia-inducible transcription factor (HIF) 1α and HIF2α, which regulate many genes involved in angiogenesis, metabolism, proliferation and survival in hypoxia, even in normoxia, and play essential roles in GIC tumourigenesis [81]. These results indicate that an unknown mechanism maintains expression of HIF1α/2α in GICs in the vascular niche or the hypoxic area.

3. Single-cell analysis for characterising heterogeneous cancer cell populations

To understand tumour heterogeneity properly, knowledge of how many types of GICs exist in GBM is essential. Many researchers have unveiled heterogeneity using two types of single-cell analyses: (1) clonal analysis of GICs and (2) direct analysis of single cells prepared from GBM (Fig. 2).

Hide et al. established single GIC clones from mouse GIC models and revealed that only 2 of 10 clones, all of which were *p53* deficient and expressed oncogenic *Ras*, retained tumourigenicity. Analysis of gene expression profiles has revealed that these tumourigenic clones differed, suggesting that mouse GIC models consist of heterogeneous GICs. By comparing the gene expression profiles of tumourigenic and non-tumourigenic clones, 547 and 402 genes were observed to increase and decrease, respectively, in both tumourigenic clones. Among these genes, the authors focused on Sox11 and Plagl1, as their expression also decreased and increased, respectively, in

human GICs. It was demonstrated that *Sox11* overexpression inhibits GIC proliferation by preventing expression of *plagl1* but that enforced expression of *plagl1* promoted tumourigenesis in non-tumourigenic clones, and the authors concluded that Sox11 and Plagl1 reciprocally regulate GIC tumourigenesis [12].

Meyer et al. established 44 single cell clones, which were directly prepared from human GBM tissues, and analysed their gene expression, proliferation, differentiation, tumourigenicity and drug resistance, observing heterogeneous expression of PTEN, EGFR and EGFRvIII and different sensitivities to TMZ in the tumourigenic clones and revealing the existence of heterogeneous GICs in human GBM [82].

Additionally, Chen et al. performed transcriptome analyses of single cells from primary and relapsed GBM and discovered three independent mutations in Ankyrin Repeat and PH Domain 1 (ASAP1), CD44 and catenin α-like 1 protein (CTNNLA1), all of which are involved in RAS/GEF/GTP signalling regulation, in relapsed GBM. Based on meta-analysis of NIH Genomic Data Commons, they confirmed expression of the three genes to be increased in GBM [83].

Because it examines the tumourigenicity of expanded lines, clonal analysis is the best method for analysing GIC heterogeneity. Nonetheless, in clonal analysis, it is necessary to verify that GICs are maintained as a homogenous population in culture. Additionally, there is concern about whether the direct analysis of single cells from GBM can unveil the characteristics of *bona fide* GICs because it is impossible to examine which single cell retains tumourigenicity. Therefore, novel methods for analysing heterogeneity in cancer still needed.

4. Discovery of chemicals and factors targeting TMZ-resistant GICs

Although radiation and anticancer drugs may kill proliferating GICs as well as cancer cells, some GICs are obviously resistant to these therapies due to enhanced DNA repair ability (e.g., Chk1/2), cytotoxicity neutralization (e.g., ALDH1A3), drug efflux (e.g., ABCG2) or their combination, leading to recurrence [11,84,85]. As GBM appears to contain heterogeneous GICs, each of which differs in sensitivity against cytotoxic compounds, the most effective therapeutic methods are to target factors/mechanisms, such as Notch, Sox2, STAT3 and EGFR, all of which are shared by all GICs. Notably, it should be considered that targeting such factors/mechanisms may cause severe side effects, with homeostasis loss, as tissue-specific stem cells very likely use the same factors/mechanisms for their maintenance and proliferation. An alternative method is to identify factors/mechanisms that specifically act on therapy-resistant GICs but not on therapy-sensitive GICs and normal cells, including tissue-specific stem cells (Fig. 3A).

Wang et al have been demonstrated that a drug combination synergistically targeting PN-GICs and MES-GICs effectively prevented the proliferation of U87 glioma cells *in vitro* [19]. These suggest that the chosen drug combination, which independently eliminates different types of GICs, is useful for GBM therapy with fewer side effects.

TMZ is currently used as a standard medicine for GBM, but its efficacy is limited, indicating the existence of TMZ-resistant tumourigenic GICs. To uncover the molecular mechanism involved in TMZ resistance, several laboratories have established TMZ-resistant GBM cells and have used them for chemical screening, knockdown/lethality screening and genome-wide CRISPR/Cas9 screening (Fig. 3B). Li et al. conducted whole-transcriptome sequencing analysis to screen TMZ-resistant

GBM cells and parental GBM cells to identify the molecular mechanism of TMZ resistance. They selected 55 microRNAs (miRs) with expression that was significantly changed by TMZ treatment. Using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses, the authors noted *miR-1268a* that was decreased by TMZ treatment. They further demonstrated that overexpression of *miR-1268a* inhibits translation of ABCC1, an ABC transporter contributing to drug exclusion, but that its knockdown increased ABCC1 in GBM cells. These findings suggest that *miR-1268a* is involved in the multidrug resistance of TMZ-resistant GBM [86].

Ding et al. used a high-throughput synthetic lethality screen with a pooled short hairpin DNA repair library, in combination with TMZ, to identify targets that enhance TMZ-induced anti-tumour effects. BRCA1, which sensitizes TMZ-induced cell death in p53 wild-type GBM cells, was identified: *BRCA1* knockdown enhanced the cytotoxicity of TMZ in *p53*-wild-type glioma sphere-forming cells (GSCs) but not in *p53*-mutant GSCs. Moreover, *BRCA1* knockdown with TMZ increased DNA damage and cell death in *p53*-wild-type GSCs, and the authors concluded that the combination of BRCA1 inhibition and TMZ can be applied for GBM therapy [87].

In a genome-wide screening with a CRISPR/Cas9 library using TMZ-resistant *EGFRvIII*-expressing U87 cells (TMZ-resistant U87-EGFRvIII) and parental U87 cells, Huang et al. identified CD28, NF-κB and NFAT pathways as the most significantly altered pathways in TMZ-resistant U87-EGFRvIII. Ingenuity pathway analysis further revealed that the EGFRvIII/PI3K/AKT/NF-κB and G protein-coupled receptor (GPCR)/PLA/PKC/NFAT pathways are most responsible for TMZ resistance in U87-EGFRvIII cells. The authors eventually determined E2F6, a target of NF-κB, to be a

TMZ resistance gene in GBM and demonstrated that either knockdown of *E2F6* or pharmacological inhibition of NF-κB/E2F6 sensitizes GBM to TMZ [88].

Teng et al. performed drug screening against TMZ-resistant GBM cells and patient-derived stem-like neurospheres. They eventually found that hydroxyurea sensitized recurrent GBM to TMZ both *in vitro* and *in vivo*, regardless of *MGMT* promoter methylation status, tumour subtype or stem cell characteristics [89].

Tsukamoto et al. succeeded in establishing TMZ-resistant GICs (GICRs) by culturing GICs with 200 μM TMZ, which is 4 times higher than that in the blood of TMZ-treated patients, for 3 weeks. The GICRs as well as GICs proliferated similarly in culture, were positive for NSC markers, and formed tumours when transplanted into the brains of immunodeficient mice, indicating that the GICRs retained the characteristics of GICs [90]. The authors then performed chemical screening to identify new compounds, which killed GICRs but did not affect normal cells including NSCs, and eventually found that 1-(3-C-ethynyl-b-D-ribopentofuranosyl) uracil (EUrd) strongly kills both GICs and GICRs in culture and eradicates GICR tumours *in vivo* by blocking pyrimidine synthesis.

Same team have performed another drug screening by collaborating with the FUJIFILM company and finally identified novel compound 10580 that targets DHODH [91]. The researchers also discovered a new metabolic mechanism that de novo pyrimidine synthesis pathway is crucial for the survival and maintenance of GICs/GICRs: *DHODH* is more highly expressed in GICs/GICRs than in various types of normal cells, including NSCs. *DHODH* knockdown kills GICs. Small amounts of uridine diphosphate, a downstream product of pyrimidine biosynthesis, rescues 10580-induced cytotoxicity in GICs/GICRs, whereas large amounts of uridine, the substrate

for the salvage pathway, are required to achieve the same results. In addition, pyrimidine is mainly synthesized through the salvage pathway in many types of normal cells and tissues, particularly in the brain. Furthermore, the authors demonstrated that 10580 induced nuclear export of SOX2 and that blocked GIC tumorigenesis in vivo. Given that 10580 administration did not show any visible toxicity in mice, they concluded that 10580 is a potential candidate compound for GBM therapy (Fig. 3C).

Wang et al. have also reported a similar result: knockdown of *DHODH* by using specific short hairpin RNA induced cell cycle arrest in GICs and inhibited their tumourigenesis. It was also demonstrated that the combination of the DHODH inhibitor teriflunomide and the PI3K inhibitor BKM120 significantly prevented GIC tumourigenesis *in vivo* [92]. This combination was utilized because the medical efficacy and/or BBB permeability of teriflunomide may not be sufficient for preventing tumourigenesis *in vivo*. Nonetheless, given that pharmaceutical companies are now developing new DHODH inhibitors, such as ASLAN003 (http://aslanpharma.com/drug/aslan003/) and BAY2402234 (https://clinicaltrials.gov/ct2/show/NCT03404726), as promising anticancer compounds for acute myeloid leukaemia, pancreatic cancer, triple-negative breast cancer and melanoma, DHODH inhibitors may be used as promising GBM eradicating drugs in the near future [93-97].

5. Conclusion

To date, it is unknown how many types of GICs exist in GBM, and it is also uncertain whether all types of GICs can be maintained using the current culture methods. Therefore, establishing tailor-made medicines that eradicate individual GBM effectively and completely is challenging. It should be noted that targeting the factors/mechanisms that are shared among all GICs may cause severe side effects, with homeostasis loss, as tissue-specific stem cells very likely use the same factors/mechanisms for their maintenance and proliferation. At the moment, the best strategy is to target factors/mechanisms that are specifically essential for therapy-resistant GICs but not for therapy-sensitive GICs and normal tissue-specific stem cells. Accordingly, researchers have found DHODH to be a promising therapeutic target for GBM and have verified DHODH inhibitors including 10580, as potential anti-GBM drugs. Using similar methods, it is highly expected that innovative therapeutic drugs/methods without side effects will be developed in the near future.

Declaration of competing interest

No potential conflicts of interest were disclosed.

Acknowledgements

References

[1] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005;352:987–96.

[2] Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.

[3] Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-73.

[4] Kondo T. Brain cancer stem-like cells. Eur J Cancer 2006;42:1237-42.

[5] Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:225-36.

[6] Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev 2015;29:1203-17.

[7] Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, et al. Cairncross, Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010;12:756-60.

[8] Globus JH, Kuhlenbeck H. The subependymal cell plate (matrix) and its relationship to brain tumors of the ependymal type. J Neuropathol Exp Neurol 1944;3:1-35.

[9] Hopewell JW, Wright EA. The importance of implantation site in cerebral carcinogenesis in rats. Cancer Res 1969;29:1927-32.

[10] Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001;15:1913-25.

[11] Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing

terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-77.

[12] Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res 2009;69:7953-59.

[13] Nishide K, Nakatani Y, Kiyonari H, Kondo T. Gliomagenesis from transformed neural stem cells depleted of prominin1-expressing cells. PLoS ONE 2009;4:e6869.

[14] Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. Stem Cells 2011;29:590-9.

[15] Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000;289:1754-7.

[16] Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 2004;18:2963–72.

[17] Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011;146:209-21.

[18] Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature 2008;455:1061-8.

[19] Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme, Science 2008;321:1807-12.

[20] Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23.

[21] Kleihues P, Ohgaki H. Primary and secondary glioblastoma: from concept to clinical diagnosis, Neuro-Oncol 1999;1:44-51.

[22] Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36, Cell 2007;128:459-75.

[23] Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations, Cancer Res 1993;53:2736-9.

[24] Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer, Nat Rev Cancer 2002;2:910-7.

[25] Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas, Cancer Res 1994;54:6321-4.

[26] Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.

[27] Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors, Oncogene 1998;16:2259-64.

[28] Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007;11:147-60.

[29] Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009;15:315-27.

[30] Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-14.

[31] Gargiulo G, Cesaroni M, Serresi M, de Vries N, Hulsman D, Bruggeman SW, et al. In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell 2013;23:660-76.

[32] Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009;29:8884-96.

[33] Gallo M, Coutinho FJ, Vanner RJ, Gayden T, Mack SC, Murison A, et al. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell 2015;28:715-29.

[34] Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.

[35] Wang L, Babikir H, Müller S, Yagnik G, Shamardani K, Catalan F, et al. The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. Cancer Discov 2019;9:1708-19.

[36] Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011;25:2594-609.

[37] Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol 2016;34:933-41.

[38] Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013;10:977-9.

[39] Gao X, Tsang JC, Gaba F, Wu D, Lu L, Liu P. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res 2014;42:e155.

[40] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013;154:442-51.

[41] Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010;10:51-7.

[42] Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505.

[43] Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7.

[44] Feng YC, Liu XY, Teng L, Ji Q, Wu Y, Li JM, et al. c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. Nat Commun 2020;11:4980.

[45] Ye W, Xu P, Jen R, Feng E, Zhong S, Li H, et al.Zeranol down-regulates p53
expression in primary cultured human breast cancer epithelial cells
through epigenetic modification. Int J Mol Sci 2011;12:1519-32.

[46] Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, et
al.A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by
p53 degradation blockage. Nat Commun 2018;9:1107.

[47] Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma:
Microenvironment and Niche Concept. Cancers (Basel) 2018;11:5.

[48] Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche
matters. Cancer Res 2006;66:4553–57.

[49] Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, et al. Periostin secreted by
glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes
malignant growth. Nat. Cell Biol 2015;17:170–82.

[50] Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen L, et al. Tumor-associated
microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1
signaling pathway. J Immunol 2012;189:444–53.

[51] Markovic DS, Glass R, Synowitz M, Rooijen N, Kettenmann H. Microglia
stimulate the invasiveness of glioma cells by increasing the activity of
metalloprotease-2. J. Neuropathol Exp Neurol 2005;64:754–62.

[52] Tartour E, Pere H, Maillere B, Terme N, Merillon N, Taieb J, et al. Angiogenesis
and immunity: A bidirectional link potentially relevant for the monitoring of
antiangiogenic therapy and the development of novel therapeutic combination with
immunotherapy. Cancer Metastasis Rev 2011;30:83–95.

[53] Hu F, Ku MC, Markovic D, Dzaye OD, Lehnardt S, Synowitz M, et al. Glioma-
associated microglial MMP9 expression is upregulated by TLR2 signaling and
sensitive to minocycline. Int J Cancer 2014;135:2569–78.

[54] Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel
esophageal cancer-related gene, downregulated by CpG island hypermethylation in
human esophageal squamous cell carcinoma. World J Gastroenterol 2003;9:1174-8.

[55] Gotze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al.
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in
colorectal carcinoma and glioma. BMC Cancer 2009;9:447.

[56] Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, Lu SH. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer 2009; 125:1505-13.

[57] Li W, Liu X, Zhang B, Qi D, Zhang L, Jin Y, et al. Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J Exp Clin Cancer Res 2010;29:89

[58] Moriguchi T, Kaneumi S, Takeda S, Enomoto K, Mishra SK, Miki T, et al. Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. Oncoimmunology 2016;5:e1242547.

[59] Moriguchi T, Takeda S, Iwashita S, Enomoto K, Sawamura T, Koshimizu U, et al. Ecrg4 peptide is the ligand of multiple scavenger receptors. Sci Rep 2018;8:4048.

[60] Lee J, Dang X, Borboa A, Coimbra R, Baird A, Eliceiri BP. Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol. 2015;17:685-96.

[61] Podvin S, Dang X, Meads M, Kurabi A, Costantini T, Eliceiri BP, et al. Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex. Inflamm Res 2015;64:107–18.

[62] Dang X, Coimbra R, Mao L, Podvin S, Li X, Yu H, et al. Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4. Cell Mol Life Sci 2019;76:5027-39.

[63] Lin Q, Liu Z, Ling F, Xu G. Astrocytes protect glioma cells from chemotherapy and upregulate survival genes via gap junctional communication. Mol Med Rep 2016;13:1329–35.

[64] Chen W, Xia T, Wang D, Huang B, Zhao P, Wang J, et al. Human astrocytes secrete IL-6 to promote glioma migration and invasion through upregulation of cytomembrane MMP14. Oncotarget 2016;7:62425–38.

[65] Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol 2015;17:1556–68.

[66] Arnò B, Grassivaro F, Rossi C, Bergamaschi A, Castiglioni V, Furlan R, et al. Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun 2014;5:5611.

[67] Zhu C, Yao WL, Tan W, Zhang CH. SDF-1 and CXCR4 play an important role in adult SVZ lineage cell proliferation and differentiation. Brain Res 2017;1657:223-31.

[68] Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 2017;549:533-7.

[69] Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al.Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 2019;573:532-8.

[70] Yu K, Lin CJ, Hatcher A, Lozzi B, Kong K, Huang-Hobbs E, et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature 2020;578:166-71.

[71] Lakkaraju A, Rodriguez-Boulan E. Itinerant exosomes: emerging roles in cell and tissue polarity. Trends Cell Biol 2008;18:199-209.

[72] Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009;8:2014-8.

[73] Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011;21:139-46.

[74] Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 2011;33:441-54.

[75] Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10:1470-6.

[76] Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 2018;7:e1412909.

[77] Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, et al. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology 2018;7:e1478647.

[78] Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, et al. Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res 2017;77:5808-19.

[79] Kathagen A, Schulte A, Balcke G, Phillips HS, Martens T, Matschke J, et al. Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells. Acta Neuropathol 2013;126:763-80.

[80] Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringnér M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013;110:7312-7.

[81] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.

[82] Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA 2015;112:851-6.

[83] Chen X, Wen Q, Stucky A, Zeng Y, Gao S, Loudon WG, et al. Relapse pathway of glioblastoma revealed by single-cell molecular analysis. Carcinogenesis 2018;39:931-6.

[84] Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 2012;107:1488-97.

[85] Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, et al. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res 2014;20:2703-13.

[86] Li Y, Liu Y, Ren J, Deng S, Yi G, Guo M, et al. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol 2018;138:499-508.

[87] Ding J, Wu S, Zhang C, Garyali A, Martinez-Ledesma E, Gao F, et al. BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening. Am J Cancer Res 2019;9:2428-41.

[88] Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, et al. Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma. Adv Sci (Weinh) 2019;6:1900782.

[89] Teng J, Hejazi S, Hiddingh L, Carvalho L, de Gooijer MC, Wakimoto H, et al. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol 2018;20:642-54.

[90] Tsukamoto Y, Ohtsu N, Echizenya S, Otsuguro S, Ogura R, Natsumeda M, et al. Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. Stem Cells 2016;34:2016-25.

[91] Echizenya S, Ishii Y, Kitazawa S, Tanaka T, Matsuda S, Watanabe E, et al. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells. Neuro Oncol 2020;22:229-39.

[92] Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci Transl Med 2019;11: eaau4972

[93] White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011;471:518-22.

[94] Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell 2016;167:171–86.

[95] Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov 2017;7:391–9.

[96] Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, et al. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. Cell Chem Biol 2018;25:705-17.

[97] Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 2019;33:2403–15.

Figure legends

Fig. 1 Tumour heterogeneity is generated by cell of origin, genetic mutation/epigenetic regulation and tumour environment factors

(A) Neural stem cells (NSCs) self-renew and generate mature neurons, astrocytes and oligodendrocytes via proliferating precursor cells (left). Similarly, glioblastoma-initiating cells (GICs) self-renew and generate differentiation marker-positive cancer cells. NSCs, oligodendrocyte precursor cells (OPCs) and astrocytes, GIC cells of origin, transform into at least 3 types of GICs when these cells acquire genetic mutations/epigenetic changes. It should be noted that OPCs acquire NSC characteristics and lose their specific characteristics in the transformation process (reversion). (B) The first hit (red) occurs in the cell of origin of GIC. During proliferation, the mutant cells acquire further hits (yellow, blue and grey), eventually generating GICs. Various combinations of hits in the p53, Rb and RTK signalling pathways can occur in proliferating mutant cells, generating GIC heterogeneity. The heterogeneous population contains both therapy-sensitive and -resistant cells. (C) Many types of tumour-surrounding cells, such as endothelial cells (EC), mesenchymal stem cells (MSCs), astrocytes, microglia/macrophages and neurons, foster GICs by maintaining stemness/proliferation (e.g., Notch signal, IL6, TGFβ, miR-1587, NLGN3) and supplying energy (e.g., L-Gln). In turn, GICs supply factors, such as TGFβ, periostin, angiogenic factors and STAT3 signalling components, and increase synapse formation through Glypican 3 to maintain their niche cells.

Fig. 2 Single cell analyses of GICs

Two single-cell analyses, clonal analysis and direct analysis of single cells, can be applied to characterize heterogeneous GICs. Notably, identification of optimized culture conditions that maintain all types of GICs as a homogenous population is essential for clonal analysis. Additionally, essential markers, which reflect tumourigenicity and therapy resistance, should be determined for direct analysis of GBM-derived single cells.

Fig. 3 Discovery of chemicals and factors targeting TMZ-resistant GICs

(A) TMZ-resistant GICs can be used for identifying critical factors/mechanisms and compounds for GBM therapy through comparison with both normal NSCs and TMZ-sensitive GICs. (B) By using TMZ-resistant GICs, various types of screenings have identified novel therapeutic targets, E3F6, *miR-1268a*, BRCA1 and DHODH, and novel anti-GBM compounds, EUrd, hydroxyurea and 10580. (C) Molecular mechanism of 10580-dependent cytotoxicity and stemness deprivation in GICs. 10580-dependent DHODH inhibition causes pyrimidine exhaustion, resulting in cell cycle arrest. Decreased pyrimidine also blocks UDP-GlcNAc production, inducing CRM1-dependent nuclear export of SOX2 in GIC.

Single cell clonal analysis

Analysis of gene expression, stemness, proliferation, motility and tumorigenicity

Direct analysis of single cells

Direct transcriptome analysis

GBM

Need optimal culture conditions that maintain all kinds of original GICs as a homogenous population

Need to identify markers that reflect tumorigenicity and therapy resistance